Paletan Pertuzumab Injection

1. Indications and Usage
Metastatic Breast Cancer: In combination with docetaxel and trastuzumab, indicated for the first-line treatment of HER2-positive metastatic or unresectable locally recurrent breast cancer.
Early Breast Cancer: In combination with docetaxel, trastuzumab, and chemotherapy, indicated for the neoadjuvant treatment of HER2-positive locally advanced, inflammatory, or early-stage breast cancer. In the adjuvant setting, it is indicated for patients at high risk of recurrence.
2. Dosage and Administration
Recommended Dosage: The recommended starting dose is 840 mg, administered as an intravenous infusion over 60 minutes. Thereafter, the maintenance dose is 420 mg every 3 weeks.
Administration Details: The drug must be diluted prior to administration and must not be administered as an intravenous push or bolus.
Combination Therapy: Pertuzumab and trastuzumab must be administered sequentially, not simultaneously. For patients receiving taxanes, pertuzumab and trastuzumab should be administered before the taxane.
3. Mechanism of Action
HER2 Inhibition: Pertuzumab is a recombinant humanized monoclonal antibody that binds to subdomain II of the HER2 receptor.
Dimerization Blockade: By binding to this site, it inhibits the heterodimerization of HER2 with other HER family members, thereby blocking downstream signaling pathways that drive cell proliferation and survival.
4. Safety and Warnings
Embryo-Fetal Toxicity: Can cause fetal harm. Effective contraception is required during treatment and for 7 months after the final dose.
Diarrhea: Diarrhea is very common and can be severe; aggressive management with antidiarrheals and hydration is required.
Left Ventricular Dysfunction: Monitor left ventricular ejection fraction (LVEF) before initiation and periodically during treatment.
Infusion-Related Reactions: Monitor for hypersensitivity reactions during and after infusion.
5. Adverse Reactions and Clinical Research
Most Common Adverse Reactions: Diarrhea, neutropenia, nausea, rash, fatigue, alopecia, and increased LVEF monitoring.
Serious Adverse Reactions: Severe diarrhea, left ventricular dysfunction, and interstitial lung disease/pneumonitis.
Clinical Research Highlights: Clinical trials (e.g., CLEOPATRA, APHINITY) demonstrated significant improvements in progression-free survival and overall survival compared to trastuzumab alone.
6. Drug Interactions
CYP Enzyme Substrates: Pertuzumab pharmacokinetics are not significantly affected by CYP-mediated interactions.
Cardiotoxic Agents: Concomitant use with anthracyclines increases the risk of cardiotoxicity; anthracyclines should be completed prior to starting this combination.
7. Pharmaceutical Information
Chemical Composition: Active ingredient: Pertuzumab (recombinant DNA-derived humanized monoclonal antibody).
Appearance: Clear to slightly opalescent, colorless to pale yellow liquid.
Packaging: Supplied in single-use glass vials (e.g., 420 mg/14 mL).
Storage: Store in a refrigerator at 2°C to 8°C; do not freeze or shake. Protect from light.